OPKO Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost Purchases 47,537 Shares of Stock

OPKO Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost bought 47,537 shares of the business’s stock in a transaction on Tuesday, January 28th. The shares were acquired at an average price of $1.47 per share, with a total value of $69,879.39. Following the completion of the purchase, the chief executive officer now directly owns 213,234,014 shares of the company’s stock, valued at approximately $313,454,000.58. The trade was a 0.02 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink.

Phillip Md Et Al Frost also recently made the following trade(s):

• On Friday, January 17th, Phillip Md Et Al Frost acquired 150,000 shares of OPKO Health stock. The shares were acquired at an average price of $1.47 per share, with a total value of $220,500.00.
• On Wednesday, January 15th, Phillip Md Et Al Frost bought 500,000 shares of OPKO Health stock. The stock was acquired at an average price of $1.48 per share, for a total transaction of $740,000.00.
• On Friday, December 13th, Phillip Md Et Al Frost bought 125,000 shares of OPKO Health stock. The shares were bought at an average cost of $1.59 per share, for a total transaction of $198,750.00.
• On Wednesday, December 11th, Phillip Md Et Al Frost acquired 500,000 shares of OPKO Health stock. The stock was purchased at an average cost of $1.56 per share, with a total value of $780,000.00.
• On Friday, November 29th, Phillip Md Et Al Frost acquired 199,072 shares of OPKO Health stock. The stock was bought at an average price of $1.53 per share, with a total value of $304,580.16.
• On Friday, November 22nd, Phillip Md Et Al Frost purchased 100,000 shares of OPKO Health stock. The stock was bought at an average cost of $1.59 per share, with a total value of $159,000.00.
• On Thursday, November 14th, Phillip Md Et Al Frost bought 100,000 shares of OPKO Health stock. The shares were purchased at an average cost of $1.62 per share, with a total value of $162,000.00.
• On Friday, November 8th, Phillip Md Et Al Frost bought 280,183 shares of OPKO Health stock. The stock was acquired at an average price of $1.50 per share, with a total value of $420,274.50.

OPKO Health Price Performance

Shares of NASDAQ OPK opened at $1.50 on Wednesday. The stock has a market cap of $1.02 billion, a price-to-earnings ratio of -7.89 and a beta of 1.63. The company has a debt-to-equity ratio of 0.30, a quick ratio of 2.69 and a current ratio of 2.97. OPKO Health, Inc. has a fifty-two week low of $0.86 and a fifty-two week high of $1.76. The firm’s 50-day simple moving average is $1.53 and its 200 day simple moving average is $1.52.

OPKO Health (NASDAQ:OPK) last announced its earnings results on Thursday, November 7th. The biotechnology company reported $0.03 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.13. OPKO Health had a negative return on equity of 9.76% and a negative net margin of 18.65%. The company had revenue of $173.60 million for the quarter, compared to analysts’ expectations of $181.32 million. During the same quarter in the previous year, the firm earned ($0.11) earnings per share. As a group, research analysts anticipate that OPKO Health, Inc. will post -0.25 earnings per share for the current fiscal year.

Institutional Investors Weigh In On OPKO Health

A number of institutional investors have recently added to or reduced their stakes in the company. Rubric Capital Management LP grew its position in OPKO Health by 9.6% during the third quarter. Rubric Capital Management LP now owns 48,706,640 shares of the biotechnology company’s stock valued at $72,573,000 after buying an additional 4,284,336 shares during the period. Assenagon Asset Management S.A. grew its position in shares of OPKO Health by 142.5% during the 3rd quarter. Assenagon Asset Management S.A. now owns 1,490,992 shares of the biotechnology company’s stock valued at $2,227,000 after acquiring an additional 876,272 shares during the period. Clearline Capital LP purchased a new stake in shares of OPKO Health during the 3rd quarter worth approximately $1,083,000. Squarepoint Ops LLC bought a new stake in shares of OPKO Health in the 2nd quarter worth approximately $592,000. Finally, Barclays PLC lifted its stake in OPKO Health by 154.5% in the third quarter. Barclays PLC now owns 543,336 shares of the biotechnology company’s stock valued at $810,000 after purchasing an additional 329,870 shares during the last quarter. 64.63% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on OPK shares. HC Wainwright reiterated a “buy” rating and set a $3.00 price objective on shares of OPKO Health in a report on Wednesday, January 8th. StockNews.com lowered OPKO Health from a “hold” rating to a “sell” rating in a report on Wednesday, January 15th. Finally, Barrington Research reaffirmed an “outperform” rating and set a $2.25 target price on shares of OPKO Health in a research report on Friday, November 8th.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.